Do analysts recommend GCTK or BIOL?

Given BIOLASE's higher possible upside, analysts clearly believe BIOLASE is more favorable than GlucoTrack. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is GCTK or BIOL more profitable?

GlucoTrack has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. GlucoTrack's return on equity of -581.98% beat BIOLASE's return on equity. Company Net Margins Return on Equity Return on Assets GlucoTrack N/A -581.98% -220.10% BIOLASE -41.65% -1,782.73% -55.31%

Do analysts rate PTHL or BIOL?

Given BIOLASE's higher probable upside, analysts clearly believe BIOLASE is more favorable than Pheton. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pheton 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, PTHL or BIOL?

Pheton has higher earnings, but lower revenue than BIOLASE. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pheton $305.22K 6.58 -$660K N/A N/A BIOLASE $48.83M 0.00 -$20.63M -$14.94 N/A

Is PTHL or BIOL more profitable?

Pheton has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Pheton's return on equity of 0.00% beat BIOLASE's return on equity. Company Net Margins Return on Equity Return on Assets Pheton N/A N/A N/A BIOLASE -41.65% -1,782.73% -55.31%

Do analysts prefer BIOL or VBIO?

Given BIOLASE's higher possible upside, research analysts clearly believe BIOLASE is more favorable than Valion Bio, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer BIOL or VBIO?

In the previous week, Valion Bio, Inc. Common Stock had 2 more articles in the media than BIOLASE. MarketBeat recorded 3 mentions for Valion Bio, Inc. Common Stock and 1 mentions for BIOLASE. BIOLASE's average media sentiment score of 1.00 beat Valion Bio, Inc. Common Stock's score of 0.30 indicating that BIOLASE is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BIOLASE 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Valion Bio, Inc. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate BIOL or RBOT?

Vicarious Surgical has a consensus price target of $7.00, indicating a potential upside of 4,017.65%. Given Vicarious Surgical's stronger consensus rating and higher possible upside, analysts plainly believe Vicarious Surgical is more favorable than BIOLASE. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Vicarious Surgical 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is BIOL or RBOT more profitable?

Vicarious Surgical has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Vicarious Surgical's return on equity of -184.13% beat BIOLASE's return on equity. Company Net Margins Return on Equity Return on Assets BIOLASE -41.65% -1,782.73% -55.31% Vicarious Surgical N/A -184.13% -112.50%

Does the media prefer BIOL or RBOT?

In the previous week, BIOLASE and BIOLASE both had 1 articles in the media. BIOLASE's average media sentiment score of 1.00 beat Vicarious Surgical's score of 0.00 indicating that BIOLASE is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BIOLASE 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vicarious Surgical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer BIOL or LYRA?

Given BIOLASE's higher probable upside, equities analysts clearly believe BIOLASE is more favorable than Lyra Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Lyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is BIOL or LYRA more profitable?

BIOLASE has a net margin of -41.65% compared to Lyra Therapeutics' net margin of -5,491.17%. Lyra Therapeutics' return on equity of -1,010.91% beat BIOLASE's return on equity. Company Net Margins Return on Equity Return on Assets BIOLASE -41.65% -1,782.73% -55.31% Lyra Therapeutics -5,491.17% -1,010.91% -58.92%

Does the media refer more to BIOL or LYRA?

In the previous week, BIOLASE and BIOLASE both had 1 articles in the media. BIOLASE's average media sentiment score of 1.00 beat Lyra Therapeutics' score of -0.71 indicating that BIOLASE is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BIOLASE 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lyra Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

BIOLASE (BIOL) Competitors

Compare

BIOL vs. GCTK, PTHL, VBIO, RBOT, and LYRA

Should you buy BIOLASE stock or one of its competitors? MarketBeat compares BIOLASE with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BIOLASE include GlucoTrack (GCTK), Pheton (PTHL), Valion Bio, Inc. Common Stock (VBIO), Vicarious Surgical (RBOT), and Lyra Therapeutics (LYRA). These companies are all part of the "medical equipment" industry.

How does BIOLASE compare to GlucoTrack?

GlucoTrack (NASDAQ:GCTK) and BIOLASE (NASDAQ:BIOL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

GlucoTrack has higher earnings, but lower revenue than BIOLASE. GlucoTrack is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlucoTrack	N/A	N/A	-$19.39M	-$18.04	N/A
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A

GlucoTrack has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. GlucoTrack's return on equity of -581.98% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GlucoTrack	N/A	-581.98%	-220.10%
BIOLASE	-41.65%	-1,782.73%	-55.31%

Given BIOLASE's higher possible upside, analysts clearly believe BIOLASE is more favorable than GlucoTrack.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

GlucoTrack has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market. Comparatively, BIOLASE has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

In the previous week, GlucoTrack and GlucoTrack both had 1 articles in the media. GlucoTrack's average media sentiment score of 1.87 beat BIOLASE's score of 1.00 indicating that GlucoTrack is being referred to more favorably in the media.

Company	Overall Sentiment
GlucoTrack	Very Positive
BIOLASE	Positive

10.9% of GlucoTrack shares are held by institutional investors. Comparatively, 8.8% of BIOLASE shares are held by institutional investors. 2.2% of GlucoTrack shares are held by company insiders. Comparatively, 0.3% of BIOLASE shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

GlucoTrack beats BIOLASE on 8 of the 13 factors compared between the two stocks.

How does BIOLASE compare to Pheton?

Pheton (NASDAQ:PTHL) and BIOLASE (NASDAQ:BIOL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

Given BIOLASE's higher probable upside, analysts clearly believe BIOLASE is more favorable than Pheton.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pheton	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Pheton has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Pheton's return on equity of 0.00% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pheton	N/A	N/A	N/A
BIOLASE	-41.65%	-1,782.73%	-55.31%

Pheton has higher earnings, but lower revenue than BIOLASE.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pheton	$305.22K	6.58	-$660K	N/A	N/A
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A

Pheton has a beta of 5.4, meaning that its stock price is 440% more volatile than the broader market. Comparatively, BIOLASE has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

8.8% of BIOLASE shares are owned by institutional investors. 0.3% of BIOLASE shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, BIOLASE had 1 more articles in the media than Pheton. MarketBeat recorded 1 mentions for BIOLASE and 0 mentions for Pheton. BIOLASE's average media sentiment score of 1.00 beat Pheton's score of 0.00 indicating that BIOLASE is being referred to more favorably in the news media.

Company	Overall Sentiment
Pheton	Neutral
BIOLASE	Positive

Summary

Pheton and BIOLASE tied by winning 6 of the 12 factors compared between the two stocks.

How does BIOLASE compare to Valion Bio, Inc. Common Stock?

BIOLASE (NASDAQ:BIOL) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Valion Bio, Inc. Common Stock has lower revenue, but higher earnings than BIOLASE. Valion Bio, Inc. Common Stock is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A
Valion Bio, Inc. Common Stock	$780K	2.06	-$8.88M	-$6.68	N/A

In the previous week, Valion Bio, Inc. Common Stock had 2 more articles in the media than BIOLASE. MarketBeat recorded 3 mentions for Valion Bio, Inc. Common Stock and 1 mentions for BIOLASE. BIOLASE's average media sentiment score of 1.00 beat Valion Bio, Inc. Common Stock's score of 0.30 indicating that BIOLASE is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BIOLASE	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Valion Bio, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Valion Bio, Inc. Common Stock's return on equity of -138.10% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BIOLASE	-41.65%	-1,782.73%	-55.31%
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%

BIOLASE has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market.

Given BIOLASE's higher possible upside, research analysts clearly believe BIOLASE is more favorable than Valion Bio, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

8.8% of BIOLASE shares are owned by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. 0.3% of BIOLASE shares are owned by company insiders. Comparatively, 2.2% of Valion Bio, Inc. Common Stock shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Valion Bio, Inc. Common Stock beats BIOLASE on 8 of the 14 factors compared between the two stocks.

How does BIOLASE compare to Vicarious Surgical?

BIOLASE (NASDAQ:BIOL) and Vicarious Surgical (NYSE:RBOT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

8.8% of BIOLASE shares are held by institutional investors. Comparatively, 47.3% of Vicarious Surgical shares are held by institutional investors. 0.3% of BIOLASE shares are held by insiders. Comparatively, 11.1% of Vicarious Surgical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, BIOLASE and BIOLASE both had 1 articles in the media. BIOLASE's average media sentiment score of 1.00 beat Vicarious Surgical's score of 0.00 indicating that BIOLASE is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BIOLASE	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vicarious Surgical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BIOLASE has higher revenue and earnings than Vicarious Surgical. Vicarious Surgical is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A

Vicarious Surgical has a consensus price target of $7.00, indicating a potential upside of 4,017.65%. Given Vicarious Surgical's stronger consensus rating and higher possible upside, analysts plainly believe Vicarious Surgical is more favorable than BIOLASE.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Vicarious Surgical	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Vicarious Surgical has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Vicarious Surgical's return on equity of -184.13% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BIOLASE	-41.65%	-1,782.73%	-55.31%
Vicarious Surgical	N/A	-184.13%	-112.50%

BIOLASE has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, Vicarious Surgical has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market.

Summary

Vicarious Surgical beats BIOLASE on 8 of the 13 factors compared between the two stocks.

How does BIOLASE compare to Lyra Therapeutics?

BIOLASE (NASDAQ:BIOL) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

8.8% of BIOLASE shares are owned by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are owned by institutional investors. 0.3% of BIOLASE shares are owned by insiders. Comparatively, 3.3% of Lyra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

BIOLASE has higher revenue and earnings than Lyra Therapeutics. Lyra Therapeutics is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A
Lyra Therapeutics	$600K	1.83	-$93.43M	-$19.15	N/A

In the previous week, BIOLASE and BIOLASE both had 1 articles in the media. BIOLASE's average media sentiment score of 1.00 beat Lyra Therapeutics' score of -0.71 indicating that BIOLASE is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BIOLASE	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lyra Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

BIOLASE has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, Lyra Therapeutics has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market.

Given BIOLASE's higher probable upside, equities analysts clearly believe BIOLASE is more favorable than Lyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

BIOLASE has a net margin of -41.65% compared to Lyra Therapeutics' net margin of -5,491.17%. Lyra Therapeutics' return on equity of -1,010.91% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BIOLASE	-41.65%	-1,782.73%	-55.31%
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%

Summary

BIOLASE beats Lyra Therapeutics on 8 of the 13 factors compared between the two stocks.

Get BIOLASE News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIOL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIOL vs. The Competition

Export

Metric	BIOLASE	Dental equipment & supplies Industry	Medical Sector	NASDAQ Exchange
Market Cap	$581K	$2.87M	$6.81B	$12.57B
Dividend Yield	N/A	N/A	2.66%	6.16%
P/E Ratio	0.00	N/A	27.52	25.33
Price / Sales	N/A	0.06	539.41	102.00
Price / Cash	N/A	N/A	48.53	58.59
Price / Book	N/A	0.01	10.94	6.61
Net Income	-$20.63M	-$60.92M	$3.57B	$336.72M

BIOLASE Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIOL BIOLASE	N/A	N/A	N/A	N/A	$581K	$48.83M	N/A	160	Positive News
GCTK GlucoTrack	0.573 of 5 stars	$0.35 -4.0%	N/A	-94.7%	$2.28M	N/A	N/A	5
PTHL Pheton	N/A	$0.32 +0.1%	N/A	-98.3%	$2.11M	$305.22K	N/A	11
VBIO Valion Bio, Inc. Common Stock	1.1282 of 5 stars	$0.54 +1.3%	N/A	-87.5%	$1.71M	$780K	N/A	10	Short Interest Increase Gap Up
RBOT Vicarious Surgical	1.7626 of 5 stars	$0.22 +15.8%	$7.00 +3,081.8%	-98.1%	$1.57M	N/A	N/A	210

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BIOL) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BIOLASE (BIOL) Competitors

BIOL vs. GCTK, PTHL, VBIO, RBOT, and LYRA

How does BIOLASE compare to GlucoTrack?

Summary

How does BIOLASE compare to Pheton?

Summary

How does BIOLASE compare to Valion Bio, Inc. Common Stock?

Summary

How does BIOLASE compare to Vicarious Surgical?

Summary

How does BIOLASE compare to Lyra Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIOL vs. The Competition

BIOLASE Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BIOLASE (BIOL) Competitors

BIOL vs. GCTK, PTHL, VBIO, RBOT, and LYRA

How does BIOLASE compare to GlucoTrack?

Which has higher valuation and earnings, GCTK or BIOL?

Is GCTK or BIOL more profitable?

Do analysts recommend GCTK or BIOL?

Which has more risk & volatility, GCTK or BIOL?

Does the media favor GCTK or BIOL?

Do insiders & institutionals believe in GCTK or BIOL?

Summary

How does BIOLASE compare to Pheton?

Do analysts rate PTHL or BIOL?

Is PTHL or BIOL more profitable?

Which has better earnings & valuation, PTHL or BIOL?

Which has more risk and volatility, PTHL or BIOL?

Do institutionals & insiders have more ownership in PTHL or BIOL?

Does the media refer more to PTHL or BIOL?

Summary

How does BIOLASE compare to Valion Bio, Inc. Common Stock?

Which has stronger valuation and earnings, BIOL or VBIO?

Does the media prefer BIOL or VBIO?

Is BIOL or VBIO more profitable?

Which has more risk and volatility, BIOL or VBIO?

Do analysts prefer BIOL or VBIO?

Do institutionals & insiders believe in BIOL or VBIO?

Summary

How does BIOLASE compare to Vicarious Surgical?

Do insiders & institutionals hold more shares of BIOL or RBOT?

Does the media prefer BIOL or RBOT?

Which has better earnings and valuation, BIOL or RBOT?

Do analysts rate BIOL or RBOT?

Is BIOL or RBOT more profitable?

Which has more volatility & risk, BIOL or RBOT?

Summary

How does BIOLASE compare to Lyra Therapeutics?

Do insiders & institutionals believe in BIOL or LYRA?

Which has better valuation and earnings, BIOL or LYRA?

Does the media refer more to BIOL or LYRA?

Which has more risk & volatility, BIOL or LYRA?

Do analysts prefer BIOL or LYRA?

Is BIOL or LYRA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIOL vs. The Competition

BIOLASE Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools